Advertisement
BIOX vs NXTS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOX is a Hold and NXTS is a Hold.
BIOX's Indicator enters downward trend
The Aroon Indicator for BIOX entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 300 similar instances where the Aroon Indicator formed such a pattern. In 262 of the 300 cases the stock moved lower. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIOX's RSI Oscillator exited the oversold zone, 32 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 62 cases where BIOX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +15.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOX advanced for three days, in 180 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
BIOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.209) is normal, around the industry mean (-0.403). P/E Ratio (-0.249) is within average values for comparable stocks, (8.767). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (0.867). Dividend Yield (0.000) settles around the average of (0.126) among similar stocks. BIOX's P/S Ratio (0.103) is slightly lower than the industry average of (1.476).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. BIOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
NXTS's RSI Indicator stays in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NXTS just turned positive on October 27, 2026. Looking at past instances where NXTS's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where NXTS advanced for three days, in 159 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NXTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NXTS as a result. In 91 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NXTS entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.405) is normal, around the industry mean (-0.403). P/E Ratio (0.029) is within average values for comparable stocks, (8.767). NXTS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.867). Dividend Yield (0.000) settles around the average of (0.126) among similar stocks. NXTS's P/S Ratio (4.315) is very high in comparison to the industry average of (1.476).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. NXTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
BIOX | NXTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 55 Fair valued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 100 | |
PRICE GROWTH RATING 1..100 | 91 | 97 | |
P/E GROWTH RATING 1..100 | 14 | 96 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NXTS's Valuation (29) in the null industry is in the same range as BIOX (55) in the Financial Conglomerates industry. This means that NXTS’s stock grew similarly to BIOX’s over the last 12 months.
NXTS's Profit vs Risk Rating (100) in the null industry is in the same range as BIOX (100) in the Financial Conglomerates industry. This means that NXTS’s stock grew similarly to BIOX’s over the last 12 months.
BIOX's SMR Rating (95) in the Financial Conglomerates industry is in the same range as NXTS (100) in the null industry. This means that BIOX’s stock grew similarly to NXTS’s over the last 12 months.
BIOX's Price Growth Rating (91) in the Financial Conglomerates industry is in the same range as NXTS (97) in the null industry. This means that BIOX’s stock grew similarly to NXTS’s over the last 12 months.
BIOX's P/E Growth Rating (14) in the Financial Conglomerates industry is significantly better than the same rating for NXTS (96) in the null industry. This means that BIOX’s stock grew significantly faster than NXTS’s over the last 12 months.
| BIOX | NXTS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 66% | 2 days ago 83% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Advances ODDS (%) | 7 days ago 76% | 6 days ago 84% |
| Declines ODDS (%) | 5 days ago 87% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIOX’s FA Score shows that 1 FA rating(s) are green while NXTS’s FA Score has 1 green FA rating(s).
- BIOX’s FA Score: 1 green, 4 red.
- NXTS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIOX’s TA Score shows that 4 TA indicator(s) are bullish while NXTS’s TA Score has 5 bullish TA indicator(s).
- BIOX’s TA Score: 4 bullish, 2 bearish.
- NXTS’s TA Score: 5 bullish, 3 bearish.
Price Growth
BIOX (@Chemicals: Agricultural) experienced а +3.12% price change this week, while NXTS (@Chemicals: Agricultural) price change was -5.50% for the same time period.
The average weekly price growth across all stocks in the @Chemicals: Agricultural industry was +0.89%. For the same industry, the average monthly price growth was -12.13%, and the average quarterly price growth was -18.57%.
Reported Earning Dates
BIOX is expected to report earnings on Nov 11, 2026.
NXTS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Chemicals: Agricultural (+0.89% weekly)The agricultural chemicals sector includes companies that produce chemical products for the agricultural industry applications like crop protection, animal health, biotechnology and pharmaceutical-related products. Some of the largest agricultural chemicals producers include Nutrien Ltd., Corteva Inc., and FMC Corporation.
Advertisement
BIOX and
Correlation & Price change
A.I.dvisor tells us that BIOX and UAN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOX and UAN's prices will move in lockstep.
| Ticker / NAME | Correlation To BIOX | 1D Price Change % | ||
|---|---|---|---|---|
| BIOX | 100% | +3.84% | ||
| UAN - BIOX | 21% Poorly correlated | -1.58% | ||
| SEED - BIOX | 20% Poorly correlated | +0.08% | ||
| IPI - BIOX | 20% Poorly correlated | -1.87% | ||
| FMC - BIOX | 20% Poorly correlated | +4.84% | ||
| SMG - BIOX | 20% Poorly correlated | +4.64% | ||
More | ||||
NXTS and
Correlation & Price change
A.I.dvisor tells us that NXTS and BIOX have been poorly correlated (+5% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NXTS and BIOX's prices will move in lockstep.
| Ticker / NAME | Correlation To NXTS | 1D Price Change % | ||
|---|---|---|---|---|
| NXTS | 100% | -9.21% | ||
| BIOX - NXTS | 5% Poorly correlated | +3.84% | ||
| CF - NXTS | 3% Poorly correlated | -2.41% | ||
| SEED - NXTS | 2% Poorly correlated | +0.08% | ||
| ICL - NXTS | -0% Poorly correlated | -0.22% | ||
| CTVA - NXTS | -3% Poorly correlated | +2.41% | ||
More | ||||